Theravance Biopharma (TBPH) Competitors $11.18 +0.14 (+1.22%) Closing price 07/3/2025 01:21 PM EasternExtended Trading$11.18 0.00 (0.00%) As of 07/3/2025 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TBPH vs. BCRX, RXRX, NAMS, INDV, CNTA, SPRY, EVO, OCUL, GRDN, and DYNShould you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include BioCryst Pharmaceuticals (BCRX), Recursion Pharmaceuticals (RXRX), NewAmsterdam Pharma (NAMS), Indivior (INDV), Centessa Pharmaceuticals (CNTA), ARS Pharmaceuticals (SPRY), Evotec (EVO), Ocular Therapeutix (OCUL), Guardian Pharmacy Services (GRDN), and Dyne Therapeutics (DYN). These companies are all part of the "med - drugs" industry. Theravance Biopharma vs. Its Competitors BioCryst Pharmaceuticals Recursion Pharmaceuticals NewAmsterdam Pharma Indivior Centessa Pharmaceuticals ARS Pharmaceuticals Evotec Ocular Therapeutix Guardian Pharmacy Services Dyne Therapeutics Theravance Biopharma (NASDAQ:TBPH) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment. Is TBPH or BCRX more profitable? BioCryst Pharmaceuticals has a net margin of -10.62% compared to Theravance Biopharma's net margin of -89.38%. BioCryst Pharmaceuticals' return on equity of 0.00% beat Theravance Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Theravance Biopharma-89.38% -32.37% -16.48% BioCryst Pharmaceuticals -10.62%N/A -11.06% Which has more risk and volatility, TBPH or BCRX? Theravance Biopharma has a beta of -0.02, meaning that its stock price is 102% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Does the media refer more to TBPH or BCRX? In the previous week, BioCryst Pharmaceuticals had 28 more articles in the media than Theravance Biopharma. MarketBeat recorded 28 mentions for BioCryst Pharmaceuticals and 0 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 0.78 beat BioCryst Pharmaceuticals' score of 0.41 indicating that Theravance Biopharma is being referred to more favorably in the media. Company Overall Sentiment Theravance Biopharma Positive BioCryst Pharmaceuticals Neutral Do institutionals and insiders believe in TBPH or BCRX? 99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 6.9% of Theravance Biopharma shares are held by insiders. Comparatively, 4.8% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has higher valuation & earnings, TBPH or BCRX? Theravance Biopharma has higher earnings, but lower revenue than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTheravance Biopharma$65.27M8.57-$56.42M-$1.18-9.48BioCryst Pharmaceuticals$450.71M4.15-$88.88M-$0.26-34.40 Do analysts rate TBPH or BCRX? Theravance Biopharma currently has a consensus target price of $16.60, indicating a potential upside of 48.41%. BioCryst Pharmaceuticals has a consensus target price of $16.70, indicating a potential upside of 86.70%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Theravance Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Theravance Biopharma 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.67BioCryst Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 SummaryBioCryst Pharmaceuticals beats Theravance Biopharma on 10 of the 17 factors compared between the two stocks. Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TBPH vs. The Competition Export to ExcelMetricTheravance BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$557.51M$2.43B$5.56B$9.04BDividend YieldN/A1.67%5.22%3.99%P/E Ratio-9.489.3527.6920.25Price / Sales8.57694.55423.80177.13Price / CashN/A158.5936.8958.10Price / Book3.134.588.035.67Net Income-$56.42M$31.34M$3.18B$249.21M7 Day Performance-0.31%3.25%2.93%3.28%1 Month Performance-0.58%3.46%1.72%3.95%1 Year Performance27.68%0.77%34.39%20.98% Theravance Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TBPHTheravance Biopharma2.0716 of 5 stars$11.19+1.2%$16.60+48.4%+27.7%$557.51M$65.27M-9.48110BCRXBioCryst Pharmaceuticals4.4655 of 5 stars$9.91-1.9%$16.56+67.1%+37.2%$2.11B$450.71M-38.12530Analyst ForecastAnalyst RevisionRXRXRecursion Pharmaceuticals1.9188 of 5 stars$4.83-4.0%$7.00+44.9%-28.1%$2.04B$58.84M0.00400Analyst ForecastNAMSNewAmsterdam Pharma2.2796 of 5 stars$18.21+1.4%$42.89+135.5%-0.8%$2.02B$45.56M0.004Positive NewsAnalyst UpgradeINDVIndivior2.0773 of 5 stars$13.95-0.4%$15.00+7.5%+6.5%$1.93B$1.19B8.191,051News CoverageCNTACentessa Pharmaceuticals3.1646 of 5 stars$13.00+4.6%$27.89+114.5%+64.0%$1.66B$6.85M0.00200SPRYARS Pharmaceuticals3.2407 of 5 stars$16.57+4.9%$31.00+87.1%+81.2%$1.55B$89.15M0.0090Insider TradeEVOEvotec1.7043 of 5 stars$3.81+1.3%$5.93+55.7%-20.8%$1.34B$862.40M0.004,827News CoveragePositive NewsOCULOcular Therapeutix3.9616 of 5 stars$8.37+3.0%$17.33+107.1%+40.3%$1.30B$63.72M-7.28230Positive NewsGRDNGuardian Pharmacy Services1.4018 of 5 stars$20.37+1.3%$25.67+26.0%N/A$1.27B$1.23B0.003,400DYNDyne Therapeutics3.4962 of 5 stars$10.16-1.6%$43.93+332.4%-73.7%$1.17BN/A0.00100 Related Companies and Tools Related Companies BCRX Alternatives RXRX Alternatives NAMS Alternatives INDV Alternatives CNTA Alternatives SPRY Alternatives EVO Alternatives OCUL Alternatives GRDN Alternatives DYN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TBPH) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 4th: 59% dividend from Bitcoin (No Crypto Needed)I've got something exciting for you this July 4th holiday... How about a 59.07% dividend from Bitcoin? Y...Investors Alley | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
